Get the Stockscreener App
154.99
0.33%
-0.52
After Hours:
154.99
Neurocrine Biosciences Inc stock is traded at $154.99, with a volume of 1.43M.
It is down -0.33% in the last 24 hours and up +1.72% over the past month.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$155.51
Open:
$156.65
24h Volume:
1.43M
Relative Volume:
1.50
Market Cap:
$15.45B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
52.54
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
+2.72%
1M Performance:
+1.72%
6M Performance:
+23.61%
1Y Performance:
+20.95%
1-Day Range:
$154.74
$160.18
1-Week Range:
$150.26
$160.18
52-Week Range:
$84.23
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
154.99 | 15.51B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
118.16 | 52.29B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.22 | 44.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.40 | 42.39B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.33 | 32.65B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
479.51 | 21.07B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Citigroup | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
RBC Capital Initiates Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $180 - 富途牛牛
Neurocrine Biosciences (NASDAQ:NBIX) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
Neurocrine Biosciences stock hits 52-week high at $157.88 By Investing.com - Investing.com Canada
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $180.00 - MarketBeat
Neurocrine Biosciences stock hits 52-week high at $157.88 - Investing.com
RBC Raises Price Target on Neurocrine Biosciences to $180 From $160, Keeps Outperform Rating - marketscreener.com
Hood River Capital Management LLC Sells 79,626 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) valuation update after NBI-1070770 Phase 2 trial failure reshapes pipeline expectations - simplywall.st
Earnings Recap: How Neurocrine Biosciences Inc stock performs in weak economyWeekly Trade Report & High Accuracy Trade Alerts - BỘ NỘI VỤ
TD Cowen Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Growth Value: How MSPRO stock compares to industry benchmarksQuarterly Performance Summary & AI Powered Market Entry Strategies - BỘ NỘI VỤ
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Brown Advisory Inc. - MarketBeat
TD Cowen Maintains Neurocrine Biosciences (NBIX) Buy Recommendation - Nasdaq
Leading Drug Stock Fights To Regain Buy Point At Key Resistance Level - Investor's Business Daily
Saturn V Capital Management LP Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Will Neurocrine Biosciences Inc. stock split again soonWeekly Loss Report & Free Fast Gain Swing Trade Alerts - Newser
Neurocrine Bio. stock price target raised to $200 from $175 at TD Cowen By Investing.com - Investing.com South Africa
Neurocrine Bio. stock price target raised to $200 from $175 at TD Cowen - Investing.com India
Why Neurocrine Biosciences Inc. (NB3) stock stays on buy listsPortfolio Gains Summary & High Accuracy Trade Signal Alerts - Newser
Dodge & Cox Increases Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
U.S. Tardive Dyskinesia Treatment Market to Reach USD 6417.43 - openPR.com
Will Neurocrine Biosciences Inc. (NB3) stock beat growth indexesOil Prices & Accurate Technical Buy Alerts - Newser
Is Neurocrine Biosciences Stock Built to Withstand a Pullback? - Trefis
Lyons (Neurocrine Biosciences director) sells $2.29m in NBIX stock - Investing.com
Neurocrine Biosciences Insider Sold Shares Worth $2,289,083, According to a Recent SEC Filing - marketscreener.com
Dir Lyons Sells 15,000 ($2.3M) Of Neurocrine Biosciences Inc [NBIX] - TradingView
What RSI levels show for Neurocrine Biosciences Inc. (NB3) stockWeekly Trend Summary & Real-Time Buy Zone Alerts - Newser
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyDollar Strength & Growth Oriented Trade Recommendations - Newser
Will Neurocrine Biosciences Inc. (NB3) stock split increase liquidityDividend Hike & Precise Entry and Exit Recommendations - Newser
Will Neurocrine Biosciences Inc. (NB3) stock benefit from sector leadershipPortfolio Profit Report & Expert Verified Stock Movement Alerts - Newser
Will Neurocrine Biosciences Inc. (NB3) stock gain from green policies2025 Institutional Moves & Weekly High Potential Alerts - Newser
Why Neurocrine Biosciences Inc. (NB3) stock remains top ratedMarket Trend Summary & Daily Technical Forecast Reports - Newser
Fisher Asset Management LLC Trims Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Earnings Notes - Trefis
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? - The Motley Fool
Dir Lyons Files To Sell 15,000 Of Neurocrine Biosciences Inc [NBIX] - TradingView
Sio Capital Management LLC Lowers Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Mackenzie Financial Corp Has $9.52 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Norges Bank Takes Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Hsbc Holdings PLC - MarketBeat
Korea Investment CORP Cuts Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Russell Investments Group Ltd. Has $10.58 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Can Neurocrine Biosciences Inc. stock attract ESG capital inflowsJuly 2025 Drop Watch & Consistent Growth Stock Picks - Newser
Neurocrine Biosciences CEO Gano Kyle sells $9.2 million in stock - MSN
Neurocrine Biosciences fails mid-stage study of depression drug - MSN
Neurocrine Biosciences Executive Sells Shares - TradingView
Neurocrine Biosciences Insider Sold Shares Worth $905,881, According to a Recent SEC Filing - marketscreener.com
Officer Benevich Sells 5,970 ($905.9K) Of Neurocrine Biosciences Inc [NBIX] - TradingView
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Virtus Advisers LLC - MarketBeat
Loomis Sayles & Co. L P Acquires New Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) Is Up 5.1% After Peer-Reviewed Study Highlights INGREZZA’s Clinical Profile - simplywall.st
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.46%
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):